Insilico Medicine announced a $5 million milestone payment from Menarini after first‑in‑patient dosing of MEN2501, an oncology candidate discovered with generative AI methods under a license to Menarini. The milestone underscores commercial validation of AI‑driven discovery when such candidates reach human dosing. Separately, a study on AI’s role in drug discovery and commercialization documented efficiency gains in discovery workflows, highlighting reduced time and resource needs when AI is integrated into target selection, screening and translational steps. Together these developments illustrate growing industry momentum behind AI as a de‑risking and acceleration tool in early discovery, while also flagging the need for rigorous clinical validation of AI‑derived molecules.